{"id":81037,"date":"2018-03-22T19:38:59","date_gmt":"2018-03-22T16:38:59","guid":{"rendered":"https:\/\/newsroom.su\/?p=81037"},"modified":"2018-03-22T19:38:59","modified_gmt":"2018-03-22T16:38:59","slug":"mallinckrodt-announces-first-investigator-award-for-pioneering-efforts-in-ecp-immunomodulation","status":"publish","type":"post","link":"https:\/\/newsroom.su\/?p=81037","title":{"rendered":"Mallinckrodt Announces First Investigator Award for Pioneering Efforts in ECP Immunomodulation"},"content":{"rendered":"<div class=\"8a53641db43077f6712193da0bbeb89a\" data-index=\"1\" style=\"float: none; margin:10px 0 10px 0; text-align:center;\">\n<script async src=\"\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js\"><\/script>\r\n<!-- 1 newsroom -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:inline-block;width:468px;height:60px\"\r\n     data-ad-client=\"ca-pub-2753775886465733\"\r\n     data-ad-slot=\"8795226203\"><\/ins>\r\n<script>\r\n(adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script>\r\n<div id=\"mpuls-widget-471\"><\/div>\r\n<script language=\"javascript\" type=\"text\/javascript\">\r\n(function() {\r\nvar useSSL = 'https:' == document.location.protocol;\r\nvar mpuls = document.createElement('script');\r\nmpuls.type = 'text\/javascript'; mpuls.async = true;mpuls.charset = 'UTF-8';\r\nmpuls.src = (useSSL ? 'https:' : 'http:') + '\/\/www.mpuls.ru\/load\/471.js';\r\nvar nrvrscr = document.getElementsByTagName('script')[0];\r\nnrvrscr.parentNode.insertBefore(mpuls, nrvrscr);\r\n})();\r\n<\/script>\n<\/div>\n<p>STAINES-UPON-THAMES, England, March 20, 2018\/PRNewswire-FirstCall\/ &#8212;<\/p>\n<p>EUR50,000 award goes to Rotherham NHS Foundation Trust Department of Haematology<\/p>\n<p>Mallinckrodt plc (NYSE: MNK), a leading specialty pharmaceutical company, today<br \/>\nannounced the inaugural recipient of its Advancing Extracorporeal Photopheresis (ECP)<br \/>\nImmunomodulation Investigator Award. The winning entry was submitted by investigator Dr.<br \/>\nNick Matthews and co-investigator Dr. Arun Alfred of the Department of Haematology at<br \/>\nRotherham NHS Foundation Trust in the United Kingdom.<\/p>\n<p>(Photo: https:\/\/mma.prnewswire.com\/media\/656235\/Mallinckrodt.jpg )<\/p>\n<p>Their proposal seeks to establish whether immunomodulation achieved through<br \/>\nextracorporeal photopheresis (ECP) used in treatment of chronic graft-versus-host disease<br \/>\n(GVHD) occurs through mediation of in vivo macrophage activation. Along with the 2018<br \/>\nInvestigator Award, the Department of Haematology at Rotherham NHS Foundation Trust will<br \/>\nreceive an educational grant of EUR50,000 to support this research. The winner was first<br \/>\nrevealed at the THERAKOS ECP Immunomodulation(TM) symposium at the 44th Annual Meeting of<br \/>\nthe European Society for Blood and Marrow Transplantation (EBMT) in Lisbon, Portugal.<\/p>\n<p>Receiving the award at EBMT 2018, on behalf of the Rotherham NHS Foundation Trust, Dr.<br \/>\nAlfred said: &#171;It&#8217;s an honour to receive the inaugural Investigator Award and we look<br \/>\nforward to sharing the outcomes of our work in due course.&#187;<\/p>\n<p>Mallinckrodt developed the Investigator Award to mark 30 years of its pioneering<br \/>\nTHERAKOS ECP Immunomodulation(TM) and it reflects the company&#8217;s ongoing commitment to the<br \/>\nscience of immunomodulation through ECP and its therapeutic applications. The award<br \/>\nrecognises individuals and institutions whose remarkable research contributes to the<br \/>\nadvancement of knowledge in this area of medicine.<\/p>\n<p>&#171;Mallinckrodt is a pioneer in ECP immunomodulation and we recently celebrated the<br \/>\n30th\u00a0anniversary of THERAKOS,&#187; said\u00a0Steve Romano, M.D., Executive Vice President and Chief<br \/>\nScientific Officer of Mallinckrodt. &#171;We are proud to support the work of those who<br \/>\ncontinue to push boundaries in the field and I congratulate Dr. Alfred and his team at the<br \/>\nRotherham NHS Foundation Trust on this recognition.&#187;<\/p>\n<p>Entries were invited from clinicians and scientists working on translational or<br \/>\noutcomes-based research, as well as collaborative projects. Submissions were assessed on a<br \/>\nrange of criteria, specifically scientific merit, novelty and feasibility.<\/p>\n<p>The 2019 Advancing ECP Immunomodulation Investigator Award will be open for entries<br \/>\nfrom September 2018. Full details on how to enter can be found at www.therakos.co.uk<br \/>\n[http:\/\/www.therakos.co.uk ].<\/p>\n<p>Mallinckrodt is the world&#8217;s only provider of approved, fully-integrated systems for<br \/>\nadministering immunomodulatory therapy through ECP. Its Therakos therapeutic platforms,<br \/>\nincluding the latest generation THERAKOS(R) CELLEX(R) Photopheresis System, are used by<br \/>\nacademic medical centres, hospitals, and treatment centres in more than 30 countries and<br \/>\nhave delivered more than 1 million treatments globally. For more information, please<br \/>\nvisit\u00a0www.therakos.co.uk [http:\/\/www.therakos.co.uk ].<\/p>\n<p>ABOUT MALLINCKRODT<\/p>\n<p>Mallinckrodt is a global business that develops, manufactures, markets and distributes<br \/>\nspecialty pharmaceutical products and therapies. Areas of focus include autoimmune and<br \/>\nrare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and<br \/>\nophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics<br \/>\nand gastrointestinal products. The company&#8217;s core strengths include the acquisition and<br \/>\nmanagement of highly regulated raw materials and specialized chemistry, formulation and<br \/>\nmanufacturing capabilities. The company&#8217;s Specialty Brands segment includes branded<br \/>\nmedicines and its Specialty Generics segment includes specialty generic drugs, active<br \/>\npharmaceutical ingredients and external manufacturing. To learn more about Mallinckrodt,<br \/>\nvisit www.mallinckrodt.com [http:\/\/www.mallinckrodt.com ].<\/p>\n<p>Mallinckrodt uses its website as a channel of distribution of important company<br \/>\ninformation, such as press releases, investor presentations and other financial<br \/>\ninformation. It also uses its website to expedite public access to time-critical<br \/>\ninformation regarding the company in advance of or in lieu of distributing a press release<br \/>\nor a filing with the U.S. Securities and Exchange Commission (SEC) disclosing the same<br \/>\ninformation. Therefore, investors should look to the Investor Relations page of the<br \/>\nwebsite for important and time-critical information. Visitors to the website can also<br \/>\nregister to receive automatic e-mail and other notifications alerting them when new<br \/>\ninformation is made available on the Investor Relations page of the website.<\/p>\n<p>Mallinckrodt, the &#171;M&#187; brand mark and the Mallinckrodt Pharmaceuticals logo are<br \/>\ntrademarks of a Mallinckrodt company. Other brands are trademarks of a Mallinckrodt<br \/>\ncompany or their respective owners. (c) 2018 Mallinckrodt Item code: PRC<br \/>\nINTL\/dvUVA\/0318\/0066. Date of preparation: March 2018.<\/p>\n<p>Photo:<br \/>\nhttps:\/\/mma.prnewswire.com\/media\/656235\/Mallinckrodt.jpg<\/p>\n<p>Source:<br \/>\nMallinckrodt plc<\/p>\n<p>Rhonda Sciarra, Senior Communications Manager<br \/>\n+1 908-238-6765, rhonda.sciarra@mnk.com<br \/>\nMeredith Fischer, Chief Public Affairs Officer<br \/>\n+1 314-654-3318, meredith.fischer@mnk.com<br \/>\nInvestor Relations<br \/>\nDaniel J. Speciale, CPA, Investor Relations and Strategy Officer+1 314-654-3638, daniel.speciale@mnk.com<\/p>\n<div class=\"8a53641db43077f6712193da0bbeb89a\" data-index=\"1\" style=\"float: none; margin:10px 0 10px 0; text-align:center;\">\n<script async src=\"\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js\"><\/script>\r\n<!-- 1 newsroom -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:inline-block;width:468px;height:60px\"\r\n     data-ad-client=\"ca-pub-2753775886465733\"\r\n     data-ad-slot=\"8795226203\"><\/ins>\r\n<script>\r\n(adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script>\r\n<div id=\"mpuls-widget-471\"><\/div>\r\n<script language=\"javascript\" type=\"text\/javascript\">\r\n(function() {\r\nvar useSSL = 'https:' == document.location.protocol;\r\nvar mpuls = document.createElement('script');\r\nmpuls.type = 'text\/javascript'; mpuls.async = true;mpuls.charset = 'UTF-8';\r\nmpuls.src = (useSSL ? 'https:' : 'http:') + '\/\/www.mpuls.ru\/load\/471.js';\r\nvar nrvrscr = document.getElementsByTagName('script')[0];\r\nnrvrscr.parentNode.insertBefore(mpuls, nrvrscr);\r\n})();\r\n<\/script>\n<\/div>\n\n<div style=\"font-size: 0px; height: 0px; line-height: 0px; margin: 0; padding: 0; clear: both;\"><\/div>","protected":false},"excerpt":{"rendered":"<p>STAINES-UPON-THAMES, England, March 20, 2018\/PRNewswire-FirstCall\/ &#8212; EUR50,000 award goes to Rotherham NHS Foundation Trust Department of Haematology Mallinckrodt plc (NYSE: MNK), a leading specialty pharmaceutical company, today announced the inaugural recipient of its Advancing Extracorporeal Photopheresis (ECP) Immunomodulation Investigator Award. The winning entry was submitted by investigator Dr. Nick Matthews and co-investigator Dr. Arun Alfred&#8230;<\/p>\n","protected":false},"author":10,"featured_media":81069,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","tstyn_error":""},"categories":[3],"tags":[52],"class_list":["post-81037","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-na-e-krane","tag-nauka"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/newsroom.su\/index.php?rest_route=\/wp\/v2\/posts\/81037","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/newsroom.su\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/newsroom.su\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/newsroom.su\/index.php?rest_route=\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/newsroom.su\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=81037"}],"version-history":[{"count":0,"href":"https:\/\/newsroom.su\/index.php?rest_route=\/wp\/v2\/posts\/81037\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/newsroom.su\/index.php?rest_route=\/wp\/v2\/media\/81069"}],"wp:attachment":[{"href":"https:\/\/newsroom.su\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=81037"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/newsroom.su\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=81037"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/newsroom.su\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=81037"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}